Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour

• Published in: EBioMedicine Vol. 57; p. 102850
• Main Authors: Wei, Zhe-Wei, Wu, Jing, Huang, Wei-Bin, Li, Jin, Lu, Xiao-Fang, Yuan, Yu-Jie, Xiong, Wen-Jun, Zhang, Xin-Hua, Wang, Wei, He, Yu-Long, Zhang, Chang-Hua
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2020; Elsevier
• Subjects: Gastrointestinal stromal tumours; Immunoscore; Prognosis; Prognostic biomarker; Research paper; Tumour-infiltrating lymphocytes; Prognosis; Immunoscore; Tumour-infiltrating lymphocytes; Gastrointestinal stromal tumours; Prognostic biomarker
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2020.102850

Accumulating evidence indicates that tumour-infiltrating lymphocytes (TILs) are the primary determinant of survival outcomes in various tumours. Thus, we sought to investigate the TIL distribution and density in gastrointestinal stromal tumours (GISTs) and to develop an immune infiltration (II)-based signature to predict prognosis. The expression of 8 immune features in the tumour centre (TC) and tumour margin (TM) and PD-L1 in 435 GIST patients was investigated by immunohistochemistry. Then, a 4-feature-based II-GIST signature integrating the CD3+ TC, CD3+ TM, CD8+ TM and CD45RO+ TM parameters was developed using a LASSO Cox regression model in the training cohort and was validated in two separate validation cohorts. High CD3+ TC, CD3+ TM, CD8+ TC, CD8+ TM, CD45RO+ TM, NKp46+ TM and CD20+ TM correlated with improved survival. Patients with high II-GIST scores have better RFS and OS outcomes than those with low II-GIST scores. Multivariable analyses demonstrated that the II-GIST signature is an independent prognostic factor. The receiver operating characteristic (ROC) curve demonstrated that the prognostic accuracy of the II-GIST signature is superior to that of the NIH risk criteria. Further analysis showed that moderate- and high-risk GIST patients with high II-GIST scores could gain survival benefits from adjuvant imatinib therapy. The novel II-GIST signature accurately predicted the survival outcomes of GIST patients. In addition, the II-GIST signature was a useful predictor of survival benefit from imatinib therapy amongst moderate- and high-risk patients with GIST. This project was supported by National Natural Science Foundation of China (81702325), Natural Science Foundation of Guangdong Province (2017A030310565), and 3&3 Project of the First Affiliated Hospital of Sun Yat-sen University.